Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 23, 1998

View Archived Issues

Company Profile: Acacia Biosciences

Orally active enkephalinase-inhibitory prodrug reported by Dainippon

SmithKline Beecham presents new azetidinones for atherosclerosis

Inhibitors of prostaglandin biosynthesis prepared at Abbott

Enantiomers of trans-benz[e]indoles selective for D3 receptors

Lilly prepares compounds for controlling TxA2

Anti-H. pylori agents from Pfizer

Princeton and Lilly collaborate on development of inhibitors of folate enzymes

CRF antagonists patented by Pfizer

Irreversible HIV protease inhibitors under evaluation at LG Chemical

Novel bone resorption inhibitors from ADIR

Desmycosin derivatives a focus of research at Pliva

TNF-alpha inhibitors disclosed by Celgene

New telomerase inhibitors from Geron

Merck & Co. describes FPTase inhibitors with improved pharmacokinetics

New class of macrolides developed at Abbott

Ontogen describes novel MDR modulators

Efficacy and safety of oral contraception demonstrated in men

Abbott presents in vitro and in vivo efficacy data on tricyclic ketolides

Lexacalcitol: a vitamin D analogue with increased potency

Clinical results reported for Servier's MDR-reversing agent S-9788

HMR's new ketolides extensively discussed at conference this week

T Cell Sciences awarded SBIR grant for atherosclerosis vaccine

Viracept approved for marketing in E.U. member countries

Alkermes, Johnson & Johnson to codevelop novel formulation of erythropoietin

Boston Life Sciences to seek U.S. approval for Therafectin

Antegren meets development criteria in phase II trial

Quilimmune-P enters phase II

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...